PLK1-IN-13
PLK1-IN-13 is a selective and orally active PLK1 inhibitor (IC50: 0.27 nM) . PLK1-IN-13 also inhibits PLK2 (IC50: 12.72 nM) and PLK3 (IC50: 4.12 nM) . PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) [1].
Product Specifications
CAS Number
3038489-48-1
UNSPSC
12352005
Target
Apoptosis; c-Myc; Polo-like Kinase (PLK)
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Field of Research
Cancer
Smiles
O=C1N(C)C2=CN=C(NC3=CC=C(C4=NN=C(CN5CCN(C)CC5)S4)C=C3OC)N=C2N(C6CCCC6)[C@@H]1CC
Molecular Formula
C29H39N9O2S
Molecular Weight
577.74
References & Citations
[1]Hou Y, et al. Discovery of novel dihydropteridone derivatives as orally bioavailable PLK1 inhibitors with reduced hERG inhibitory activity for acute myeloid leukemia treatment. Eur J Med Chem. 2025 May 5;289:117480.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
PLK1; PLK2; PLK3
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC042848-100 1x 100 µL
Fibronectin (Fn-3), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC040676-500 1x 500 µL
MUC18 / Mucin 18 / CD146 (OJ79c), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471884-100 1x 100 µL
Thymidylate Synthase (5-FU Resistance Marker) (TYMS/1884), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470634-100 1x 100 µL
CD146 / MCAM / MUC18 / Mucin 18 (C146/634), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details